Document is current
Any future updates will be listed below
-
Authors
Do, Thien Phu
Dømgaard, Mikala
Stefansen, Simon
Kristoffersen, Espen Saxhaug
Ashina, Messoud
Hansen, Jakob Møller
- License Information
-
More Information
Article History
Received: 12 July 2021
Accepted: 28 March 2022
First Online: 1 April 2022
Declarations
:
: Protocols for conducting of surveys is subject to exemption from processing at the National Committee on Health Research Ethics in Denmark. The ethical approval for this study was exempted by the National Committee on Health Research Ethics in Denmark. All methods were carried out in accordance with the Declaration of Helsinki. Informed consent was obtained from all subjects and/or their legal guardian(s). We handled survey data confidentially and maintained anonymity of respondents throughout the study.
: Not applicable.
: ESK is supported by University of Oslo and Akershus University Hospital. MA is a consultant, speaker, or scientific advisor for AbbVie, Allergan, Amgen, Eli Lilly, Lundbeck, Novartis, and Teva and a primary investigator for ongoing AbbVie/Allergan, Amgen, Eli Lilly, Lundbeck, Novartis, and Teva trials. Messoud Ashina has no ownership interest and does not own stocks of any pharmaceutical company. Messoud Ashina serves as associate editor of Cephalalgia, associate editor of the Journal of Headache and Pain, and associate editor of Brain. TPD, MD, SS, and JMH report no conflicts of interest.
